ALPPS手术基准结局的定义
该研究基于国际ALPPS注册数据库1036例患者,筛选出120例(12%)符合四项标准的基准病例,采用基准法建立10个临床相关领域的结局参考值。结果显示ALPPS的基准结局与其他类型大范围肝切除术相似,基准截断值可用于比较不同手术方式及评估高风险患者群体。
要点
- ALPPS基准病例定义为≤67岁、结直肠癌肝转移、无同期腹部手术且中心完成≥30例。
- 基准值包括二期完成率≥96%、二期术后肝衰竭≤5%、总并发症≤65%。
- 基准分析提示ALPPS结局与其他大范围肝切除术相似。
核心结论
- 基准分析为ALPPS设定了关键参考值,提示其结局与其他类型大范围肝切除术相似。
- 基准截断值可作为比较不同手术方式及评估高风险患者或非结直肠癌转移适应症的有效工具。
研究设计与样本
- 研究基于国际ALPPS注册数据库,共1036例患者,其中120例(12%)符合基准病例标准。
- 基准病例需满足4项标准:年龄≤67岁、结直肠癌转移、无同期腹部手术、中心完成≥30例。
- 基准值定义为各中心中位结局参数的第75百分位数,涵盖10个临床相关领域。
主要发现
- 二期完成率≥96%,二期术后肝衰竭(ISGLS标准)≤5%。
- ALPPS一期和二期后ICU停留分别≤1天和≤2天,间隔期≤16天,二期后住院时间≤10天。
- 一期和二期合并总并发症率≤65%,主要并发症(Clavien-Dindo分级≥3a)≤38%,90天综合并发症指数≤22。
- 30天、90天和6个月死亡率分别≤4%、≤5%和6%。
- 总体1年生存率≥86%,无复发生存率≥50%,无肝肿瘤生存率≥57%,无肝外疾病生存率≥65%。
关键数值与推荐
- 二期完成率≥96%。
- 二期术后肝衰竭(ISGLS标准)≤5%。
- 一期和二期后ICU停留分别≤1天和≤2天,间隔期≤16天,二期后住院时间≤10天。
- 总并发症率≤65%,主要并发症(≥3a级)≤38%,90天综合并发症指数≤22。
- 30天、90天和6个月死亡率分别≤4%、≤5%和6%;总体1年生存率≥86%,无复发生存率≥50%,无肝肿瘤生存率≥57%,无肝外疾病生存率≥65%。
临床怎么用
- 基准截断值可用于与其它手术方式比较ALPPS的结局。
- 基准值有助于评估高于基准风险的患者群体或非结直肠癌转移适应症的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to use the concept of benchmarking to establish robust and standardized outcome references after the procedure ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy). BACKGROUND AND AIMS: The recently developed ALPPS procedure, aiming at removing primarily unresectable liver tumors, has been criticized for safety issues with high variations in the reported morbidity/mortality rates depending on patient, disease, technical characteristics, and center experience. No reference values for relevant outcome parameters are available. METHODS: Among 1036 patients registered in the international ALPPS registry, 120 (12%) were benchmark cases fulfilling 4 criteria: patients ≤67 years of age, with colorectal metastases, without simultaneous abdominal procedures, and centers having performed ≥30 cases. Benchmark values, defined as the 75th percentile of the median outcome parameters of the centers, were established for 10 clinically relevant domains. RESULTS: The benchmark values were completion of stage 2: ≥96%, postoperative liver failure (ISGLS-criteria) after stage 2: ≤5%, ICU stay after ALPPS stages 1 and 2: ≤1 and ≤2 days, respectively, interstage interval: ≤16 days, hospital stay after ALPPS stage 2: ≤10 days, rates of overall morbidity in combining both stage 1 and 2: ≤65% and for major complications (grade ≥3a): ≤38%, 90-day comprehensive complication index was ≤22, the 30-, 90-day, and 6-month mortality was ≤4%, ≤5%, and 6%, respectively, the overall 1-year, recurrence-free, liver-tumor-free, and extrahepatic disease-free survival was ≥86%, ≥50%, ≥57%, and ≥65%, respectively. CONCLUSIONS: This benchmark analysis sets key reference values for ALPPS, indicating similar outcome as other types of major hepatectomies. Benchmark cutoffs offer valid tools not only for comparisons with other procedures, but also to assess higher risk groups of patients or different indications than colorectal metastases.
引用
- Raptis DA, Linecker M, Kambakamba P, et al. Defining Benchmark Outcomes for ALPPS. Ann Surg. 2019. PMID: 31592812. doi:10.1097/SLA.0000000000003539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。